Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Talfirastide (TXA127) is a synthetic heptapeptide formulation of the naturally occurring endogenous peptide angiotensin-(1-7), which is a key component of the alternative renin-angiotensin system (RAS). It acts primarily as an agonist of the G-protein coupled Mas receptor (MAS1), counteracting the vasoconstrictive, inflammatory, and fibrotic effects of the classical RAS pathway (mediated by angiotensin II and the AT1 receptor). Talfirastide has been investigated for various indications, including ischemic stroke recovery, Duchenne muscular dystrophy (DMD)-associated cardiomyopathy, recessive dystrophic epidermolysis bullosa (RDEB), and COVID-19-associated acute respiratory distress syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on talfirastide.